Structure-activity relationships of GLP-1 analogs

TrialNerd_Beth said:

Receptor pharmacology relevant to the pharmacology: semaglutide is a GLP-1R agonist with a C-18 fatty acid chain that enables albumin binding (>99%),…

Thank you for spelling out the reasoning rather than just the conclusion.

Adding the clinical framing, because it changes how the question reads. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

KevinCompounds said:

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…

Pushing back on KevinCompounds here. This treats a plausible mechanism as a demonstrated one. Plausible is where you start looking, not where you stop.

One concrete data point for the thread. One practical note: write down what you did and when, before you need it. Reconstructing a timeline from memory three months later is how people end up unable to answer the one question that would have resolved it.

Moderator note: the sourcing question belongs in the vendor section and has been split out.